Linked Life Data

21081161

Source:http://linkedlifedata.com/resource/pubmed/id/21081161

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-12-27
pubmed:abstractText
Tranilast (TL) has been clinically used for the treatment of airway inflammatory diseases, although the clinical use of TL is limited because of its poor solubility and systemic side effects. To overcome these drawbacks, a novel respirable powder of TL (CSD/TL-RP) for inhalation therapy was developed using nanocrystal solid dispersion of TL (CSD/TL). Stability study on CSD/TL-RP was carried out with a focus on inhalation performance. Even after 6 months of storage at room temperature, there were no significant morphological changes in micronized particles on the surface of carrier particles as compared with that before storage. Cascade impactor analyses on CSD/TL-RP demonstrated high inhalation performance with emitted dose and fine particle fraction (FPF) of ca. 98% and 60%, respectively. Long-term storage of CSD/TL-RP resulted in only a slight decrease in FPF value (ca. 54%). Inhaled CSD/TL-RP could attenuate antigen-induced inflammatory events in rats, as evidenced by marked reduction of granulocytes in bronchoalveolar lavage fluid and inflammatory biomarkers such as eosinophil peroxidase, myeloperoxidase, and lactate dehydrogenase. These findings were consistent with decreased expression levels of mRNAs for nuclear factor-kappa B and cyclooxygenase-2, typical inflammatory mediators. Given these findings, inhalable TL formulation might be an interesting alternative to oral therapy for the treatment of asthma and other airway inflammatory diseases with sufficient dispersing stability.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1873-3441
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
77
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
178-81
pubmed:meshHeading
pubmed-meshheading:21081161-Administration, Inhalation, pubmed-meshheading:21081161-Animals, pubmed-meshheading:21081161-Anthranilic Acids, pubmed-meshheading:21081161-Anti-Allergic Agents, pubmed-meshheading:21081161-Asthma, pubmed-meshheading:21081161-Biological Markers, pubmed-meshheading:21081161-Bronchoalveolar Lavage Fluid, pubmed-meshheading:21081161-Cyclooxygenase 2, pubmed-meshheading:21081161-Drug Compounding, pubmed-meshheading:21081161-Drug Stability, pubmed-meshheading:21081161-Dry Powder Inhalers, pubmed-meshheading:21081161-Granulocytes, pubmed-meshheading:21081161-Inflammation Mediators, pubmed-meshheading:21081161-Lung, pubmed-meshheading:21081161-Male, pubmed-meshheading:21081161-NF-kappa B, pubmed-meshheading:21081161-Nanoparticles, pubmed-meshheading:21081161-Ovalbumin, pubmed-meshheading:21081161-Powders, pubmed-meshheading:21081161-Pulmonary Disease, Chronic Obstructive, pubmed-meshheading:21081161-RNA, Messenger, pubmed-meshheading:21081161-Rats, pubmed-meshheading:21081161-Rats, Sprague-Dawley
pubmed:year
2011
pubmed:articleTitle
Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
pubmed:affiliation
Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence Program, University of Shizuoka, Shizuoka, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't